Answers are grounded in this paper and cite their sources.
Pathological aggregation of α‐synuclein drives neuronal loss in Parkinson's disease. We therefore tested two optimized all‐ d ‐peptides, SVD‐17 and SVD‐1a, alongside the prototype SVD‐1. Surface plasmon resonance revealed that SVD‐17 binds monomeric α‐synuclein with a nanomolar K D of 1.09 nM. In vitro, SVD‐17 and SVD‐1a dismantled existing fibrils, rendering 50 % of them seeding‐incompetent at 1.4 µM and 5.1 µM, respectively, and suppressed seeded aggregation in HEK293 α‐synuclein biosensor cells with an IC 50 of 1.6 µM. Hemizygous TgM83 +/− mice received continuous subcutaneous infusion of each peptide for 3 months following intraperitoneal fibril seeding and were then monitored for neurological decline. Treatment with SVD‐17 or SVD‐1a extended median survival by 14% and 15%, whereas SVD‐1 provided no significant benefit. Collectively, SVD‐17 and SVD‐1a bind α‐synuclein with high affinity, disaggregate pathogenic assemblies, block further polymerization, and improve outcomes in a stringent in vivo model, underscoring their potential as disease‐modifying therapeutics for Parkinson's disease and other synucleinopathies.
No takes yet. Share an insight, caveat, or question.
Reithofer et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: